Compare · BNTX vs KYMR
BNTX vs KYMR
Side-by-side comparison of BioNTech SE (BNTX) and Kymera Therapeutics Inc. (KYMR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNTX and KYMR operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $21.49B, about 3.5x KYMR ($6.08B).
- Over the past year, BNTX is down 20.4% and KYMR is up 58.8% - KYMR leads by 79.2 points.
- KYMR has been more active in the news (11 items in the past 4 weeks vs 8 for BNTX).
- Both have 25 recent analyst ratings on file.
- Company
- BioNTech SE
- Kymera Therapeutics Inc.
- Price
- $86.70+1.43%
- $74.84+1.33%
- Market cap
- $21.49B
- $6.08B
- 1M return
- -7.86%
- -13.12%
- 1Y return
- -20.43%
- +58.79%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 8
- 11
- Recent ratings
- 25
- 25
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Kymera Therapeutics Inc.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Latest BNTX
- SEC Form 6-K filed by BioNTech SE
- The Multi-Billion-Dollar Search for Better Glioblastoma Treatments
- SEC Form 6-K filed by BioNTech SE
- Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
- BioNTech upgraded by UBS with a new price target
- Bernstein initiated coverage on BioNTech with a new price target
- SEC Form 6-K filed by BioNTech SE
- BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
- SEC Form 6-K filed by BioNTech SE
- BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
Latest KYMR
- Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration
- SEC Form 8-K filed by Kymera Therapeutics Inc.
- Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations
- Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses
- Chief Financial Officer Jacobs Bruce N. exercised 12,653 shares at a strike of $2.08, increasing direct ownership by 5% to 260,241 units (SEC Form 4)
- Chief Operating Officer Chadwick Jeremy G sold $1,373,290 worth of shares (17,184 units at $79.92) as part of a pre-agreed trading plan, decreasing direct ownership by 28% to 44,018 units (SEC Form 4) to satisfy withholding obligation
- Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
- SEC Form 144 filed by Kymera Therapeutics Inc.
- SEC Form 144 filed by Kymera Therapeutics Inc.
- Director Esposito Pamela exercised 1,000 shares at a strike of $31.20 (SEC Form 4)